Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 3/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498161 | 0.89 | HRH3 (0.59) | HRH3MMP13TP53SLC5A7 | |
| SCHEMBL4504572 | 0.86 | HRH3 (0.55) | HRH3MMP13ACHETP53ALDH1A1 | |
| SCHEMBL4666174 | 0.78 | ROCK2 (0.59) | KMT2ACCR3MMP13MAPK14ALDH1A1 | |
| SCHEMBL5133184 | 0.78 | HRH3 (0.50) | HRH3SLC5A7 | |
| SCHEMBL3035661 | 0.76 | MMP13 (0.76) | MMP13ALDH1A1LMNAHPGD | |
| SCHEMBL4933009 | 0.76 | SLC5A7 (0.57) | MEN1KMT2AMMP13MAPK14ALDH1A1 | |
| SCHEMBL15028217 | 0.75 | MMP13 (0.67) | MEN1KMT2AMMP13MAPK14ALDH1A1 | |
| SCHEMBL4500972 | 0.75 | HRH3 (0.58) | KMT2AHRH3MMP13ACHEDRD4 | |
| SCHEMBL4666181 | 0.75 | OPRK1 (0.61) | MEN1KMT2AMMP13MAPK14HPGD | |
| SCHEMBL4932164 | 0.75 | SLC5A7 (0.68) | MEN1KMT2ACCR3MMP13MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608617-B2 | Naphthaline derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1755593-B1 | NAPHTHALENE DERIVATIVES USEFUL AS HISTAMINE-3-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-20070265254-A1 | Naphthaline derivatives as H3 inverse agonists | MCARTHUR SILVIA G | 2007-11-15 | — | — | US | disclosed |
| US-7259158-B2 | Naphthaline derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1755593-A1 | NAPHTHALINE DERIVATIVES USEFUL AS HISTAMINE-3-RECEPTOR LIGANDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060009449-A1 | Naphthaline derivatives as H3 inverse agonists | HOFFMAN-LA ROCHE INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005117865-A1 | NAPHTHALINE DERIVATIVES USEFUL AS HISTAMINE-3-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265254-A1 | Naphthaline derivatives as H3 inverse agonists | HRH3, HRH4, HRH1 | MEN1 2140/4885KMT2A 588/4885HRH3 1/4885 |
| US-20060009449-A1 | Naphthaline derivatives as H3 inverse agonists | HRH3, HRH4, HRH1 | MEN1 2140/4885KMT2A 588/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.